Treatment of Diseases and Conditions Caused by Increased Vascular Permeability

Abstract

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

1 .- 15 . (canceled) 
     
     
         16 . A method for treating a pulmonary disease or condition caused by or exhibiting increased vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of Extraembryonic Amnion-derived Cellular Cytokine Secreting Solution (ECS) cell conditioned medium, wherein the ECS cell conditioned medium comprises physiological concentrations of VEGF, TGFβ, Angiogenin, PDGF, TIMP-1 and TIMP-2, and wherein the physiological range is ˜5-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and wherein the pulmonary disease or condition is selected from the group consisting of pulmonary edema, pulmonary fibrosis, and acute respiratory distress syndrome. 
     
     
         17 . The method of  claim 16  wherein the ECS conditioned medium is Amnion-derived Cellular Cytokine Solution (ACCS). 
     
     
         18 . The method of  claim 17  wherein the ACCS is formulated for parenteral administration.